Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Corvus Pharmaceuticals, Inc.
13D/A
CRVS · 221015100
|
3.9% |
2/5/2026
Event 1/23/2026
|
|||
| Adams Street Partners, LLC | 3.9% | ||||
| Adams Street 2011 Direct Fund LP | 0.8% | ||||
| Adams Street 2012 Direct Fund LP | 0.9% | ||||
| Adams Street 2013 Direct Fund LP | 0.6% | ||||
| Adams Street 2014 Direct Fund LP | 0.9% | ||||
| Adams Street 2015 Direct Venture/Growth Fund LP | 0.1% | ||||
| Adams Street 2016 Direct Venture/Growth Fund LP | 0.1% | ||||
| Adams Street 2017 Direct Venture/Growth Fund LP | 0.1% | ||||
| Adams Street 2018 Direct Venture/Growth Fund LP | 0.2% | ||||
| Adams Street Venture/Growth Fund VI LP | 0.3% | ||||
|
Mineralys Therapeutics, Inc.
13G/A
MLYS · 603170101
|
2.3% |
2/14/2025
Event 12/31/2024
|
|||
| Adams Street Partners, LLC | 2.3% | ||||
| Adams Street 2016 Direct Venture/Growth Fund LP | 0.2% | ||||
| Adams Street 2017 Direct Venture/Growth Fund LP | 0.2% | ||||
| Adams Street 2018 Direct Venture/Growth Fund LP | 0.4% | ||||
| Adams Street 2019 Direct Growth Equity Fund LP | 0.2% | ||||
| Adams Street 2020 Direct Growth Equity Fund LP | 0.2% | ||||
| Adams Street 2021 Direct Growth Equity Fund LP | 0.2% | ||||
| Adams Street Growth Equity Fund VII LP | 0.9% | ||||